TP53 and acute myeloid leukemia: In another study by Kuskin et al., the mutational profile study of AML submitted to HSCT confirmed an increased risk of relapse in patients with FLT3, TP53, and WT1 mutations, while a lower risk of relapse was found for isolated DNMT3A-mutated patients.